Novo Nordisk gets Wegovy approved in China – stock hits a new record
Novo Nordisk’s popular weight loss drug Wegovy has been approved for the treatment of severe obesity in China. “We can confirm that Wegovy has been approved in China for the treatment of severe obesity or obesity with at least one weight-related comorbidity,” Novo Nordisk writes to Ritzau. China has previously been described as a market […]
Full version of this article is only available to subscribers.
Already a subscriber, sign in here:
Gain unlimited access to all of The Copenhagen Post
Our independent reporting can only be published with support from our readers.
Monthly subscription
119
DKK/month.
(Billed once a month)
Give us a try
6 month subscription
99
DKK/month.
(Billed twice a year)
Yearly subscription
79
DKK/month.
(Billed once a year)
The post Novo Nordisk gets Wegovy approved in China – stock hits a new record appeared first on The Copenhagen Post.